- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
CMP Pharma Releases Liqrev, First FDA-Approved Liquid Suspension of Sildenafil
Medicine created for patients with difficulty swallowing tablets.
CMP Pharma, a pharmaceutical manufacturer, announced that Liqrev, the first FDA-approved ready-made oral liquid of sildenafil, is now available. Created for patients with the inability to swallow tablets, the medication is designated for the treatment of pulmonary arterial hypertension.
"Liqrev is for patients who need a liquid formulation because they have difficulty swallowing tablets. This product is a nice addition to our portfolio of liquids for patients with pulmonary arterial hypertension (PAH)," said Gerald Sakowski, CEO, CMP Pharma, Inc.
Reference: CMP Pharma, Inc Announces that Liqrev®, the First and Only Ready-made FDA-approved Liquid Suspension of Sildenafil is Now Available. PR Newswire. June 21, 2023. Accessed June 22, 2023. https://www.prnewswire.com/news-releases/cmp-pharma-inc-announces-that-liqrev-the-first-and-only-ready-made-fda-approved-liquid-suspension-of-sildenafil-is-now-available-301856229.html
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.
